Mark Campbell, MD
Endocrinology, Diabetes & Metabolism · Altoona, PANPI 1306841952
Payments from drug & device makers
Across 441 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amneal Pharmaceuticals LLC$1K
- Amgen$1K
- Sanofi-aventis U.S. LLC$937
- Lilly USA, LLC$886
- Corcept Therapeutics$605
- Dexcom, Inc.$390
- plus $3K from 29 others
What the payments were for
- Food & beverage$7,88899%
- Education$841%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amneal Pharmaceuticals LLC | 59 | $1,136 |
| Amgen | 58 | $1,003 |
| Sanofi-aventis U.S. LLC | 55 | $937 |
| Lilly USA, LLC | 50 | $886 |
| Corcept Therapeutics | 35 | $605 |
| Dexcom, Inc. | 19 | $390 |
| Novo Nordisk | 19 | $320 |
| Abbott | 15 | $283 |
| Kyowa Kirin, Inc. | 12 | $253 |
| Amarin Pharma, Inc. | 13 | $219 |
| Johnson & Johnson | 8 | $188 |
| Bayer | 11 | $186 |
| AstraZeneca | 12 | $179 |
| Xeris Pharmaceuticals, Inc. | 9 | $162 |
| Merck | 9 | $140 |
| Insulet Corporation | 9 | $139 |
| AbbVie | 7 | $130 |
| Cequr Corporation | 2 | $117 |
| Esperion Therapeutics, Inc. | 5 | $86 |
| IBSA Pharma Inc. | 4 | $82 |
| Boehringer Ingelheim | 5 | $81 |
| Radius Health, Inc. | 5 | $79 |
| Tandem Diabetes Care, Inc. | 4 | $62 |
| Ultragenyx Pharmaceutical Inc. | 2 | $41 |
| Shire North American Group Inc | 3 | $39 |
| Novartis | 2 | $33 |
| Averitas Pharma Inc. | 1 | $30 |
| Ascendis Pharma Endocrinology Inc | 1 | $26 |
| Madrigal Pharmaceuticals | 1 | $24 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| Pfizer | 1 | $21 |
| Ascensia Diabetes Care US Inc. | 1 | $20 |
| Medtronic | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Recordati_rare_diseases_inc. | 1 | $13 |
How this compares
$7,972 in reported general payments places this provider in the 70th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 188 | $253,512 |
| MounjaroTirzepatide | 161 | $243,364 |
| JardianceEmpagliflozin | 130 | $167,614 |
| RybelsusSemaglutide | 67 | $107,921 |
| TrulicityDulaglutide | 47 | $73,958 |
| Repatha SureclickEvolocumab | 63 | $57,868 |
| Humalog Kwikpen U-100Insulin Lispro | 119 | $40,263 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 80 | $39,078 |
| FarxigaDapagliflozin Propanediol | 35 | $33,865 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 230 | $31,388 |
| Humalog Kwikpen U-200Insulin Lispro | 25 | $26,990 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $21,977 |
| Novolog FlexpenInsulin Aspart | 72 | $21,004 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $19,306 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 28 | $17,084 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $320 | $361,433255 claims |
| Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro | $886 | $317,814219 claims |
| Boehringer IngelheimJardiance | $81 | $167,614130 claims |
| AstraZenecaFarxiga | $179 | $33,86535 claims |
| AbbVieSynthroid | $130 | $14,912401 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $1,136 | $7,853863 claims |
| Sanofi-aventis U.S. LLCLantus | $937 | $3,81633 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
Other endocrinology, diabetes & metabolism in Altoona
- Mona Al MukaddamPhiladelphia$3.9M
- Serge JabbourPhiladelphia$3.1M
- Mihaela BiscoveanuPhiladelphia$1.5M
- Barbara SimonPhiladelphia$1M
- Mitchell LazarPhiladelphia$1M
- Vijay BahlPittsburgh$998K
- Intekhab AhmedPhiladelphia$926K
- Erin KershawPittsburgh$804K
- Geraldo SaavedraWhitehall$698K
- Arvind CavaleFeasterville Trevose$662K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.